Medicinal Chemistry of Sirtuin Inhibitors

Author: Chen, L.

Source: Current Medicinal Chemistry, Volume 18, Number 13, May 2011 , pp. 1936-1946(11)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

As members of Class III histone deacetylases (HDACs), sirtuins use stoichiometric nicotinamide adenine dinucleotide (NAD+) to remove the acetyl group from N-acetyl-lysines of histones or non-histone proteins. Sirtuins have been implicated in metabolic diseases, cancer, and neurodegenerative diseases, constituting a promising target for drug discovery. While the early sirtuin inhibitors mimicked NAD+ or substrate peptides, high-throughput and in silico screenings have identified a wide range of core structures, many of which have been subjected to medicinal chemistry efforts. This review outlines inhibitor chemotypes, and their chemical modifications and biological evaluations, highlighting strategies to enhance inhibitory activity and selectivity among isoforms.

Keywords: Histone deacetylase; NAD+; Sirtuin; Sirtuin inhibitor; Cancer therapy; Drug discovery; Drug design; high-throughput screening; virtual screening; phenotypic screening

Document Type: Research article

DOI: http://dx.doi.org/10.2174/092986711795590057

Publication date: 2011-05-01

More about this publication?

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.